Results of the ISAR-REACT 4 study have shown that combined therapy of abciximab and unfractionated heparin is not associated with a lower 30-day rate of death, large recurrent myocardial infarction, urgent target-vessel revascularization, or major bleeding than bivalirudin therapy (10.9% vs 11.0%; relative risk 0.99, 95% CI 0.74–1.32, P = 0.94) in patients with acute non-ST-segment elevation myocardial infarction (NSTEMI) who were undergoing percutaneous coronary intervention (PCI). However, more major bleeding within 30 days was noted for the abciximab plus heparin group (4.6% vs 2.6%; relative risk 1.84, 95% CI 1.10–3.07, P = 0.02). The investigators believe that their results “support the use of bivalirudin as an effective and safe antithrombotic drug during PCI in patients with NSTEMI.”